The mechanism of Wumei Wan on treating diabetes enteropathy based on the network pharmacology

Objective:To explore the potential mechanism of Wumei Wan(WMW)in treating diabetes enteropathy(DE)basing on network pharmacology.Methods:The effective compound of WMW were collected by TCMSP,the potential target of WMW was obtained by means of PubChem and Swiss target prediction online tools,and the disease target of DE was obtained by Genecards,TTD and DisGeNET databases,Cytoscape 3.7.2 software was used to construct active ingredients of WMW-potential target-DE network,protein interaction network(PPI)was constructed by STRING database.In order to understanding the mechanism of WMW treating in DE,Omicshare platform was used for GO analysis and KEGG pathway enrichment analysis.The analysis results were verified through docking by Discovery Studio 2016.Results:Total of 128 active components and 139 targets of WMW were screened out from the ten drugs.A total of 714 disease targets were screened out from the disease databases.24 common targets were identified from both WMW and DE.AKT1,MMP9,SRC,PTGS2,PPARG,NOS2,etc.are potential major targets of WMW in the treatment of DE.61 entries(p<0.05)were enriched in GO biological process function related to fatty acid anabolism and ligand receptor binding,as unsaturated fatty acid metabolic process,icosanoid metabolic process,enzyme linked receptor protein signaling pathway,protein amino acid phosphorylation,cellular response to insulin stimulus.A total of 72 signaling pathways were obtained through KEGG pathway analysis(p<0.05).The signaling pathways closely related to DE are including relaxin signaling pathway,EGFR tyrosine kinase inhibitor resistance,CLRs signaling pathway,and VEGF signaling pathway.Conclusion:This study preliminarily revealed the material basis and mechanism of WMW in the treatment of DE from the synergistic aspects of intestinal immune balance,gastrointestinal wall structure reconstruction,intestinal microvascular disorder and neuronal activity.